Autosomal recessive centronuclear myopathy
aw-toh-SOH-muhl ree-SEH-siv sen-troh-NOO-klee-er my-AH-puh-thee
Also known as: ARCNM, centronuclear myopathy type 2
At a Glance
What is Autosomal recessive centronuclear myopathy?
Autosomal recessive centronuclear myopathy is a rare genetic disorder that primarily affects the muscles used for movement. The condition is caused by mutations in specific genes that are inherited from both parents. It affects the musculoskeletal system, leading to muscle weakness and poor muscle tone. Symptoms often appear in infancy or early childhood and may include difficulty walking, delayed motor milestones, and muscle fatigue. As the disease progresses, individuals may experience respiratory difficulties and require assistance with breathing. Early diagnosis is crucial to manage symptoms and improve quality of life. The condition can have a significant impact on family life, requiring ongoing medical care and support. Prognosis varies, but many individuals live into adulthood with supportive care. Daily life for affected individuals may involve physical therapy, use of mobility aids, and adaptations for daily activities. The condition does not typically affect intelligence, allowing individuals to lead fulfilling lives with appropriate support. Families may benefit from genetic counseling to understand the inheritance pattern and risks for future children.
Medical Definition
Autosomal recessive centronuclear myopathy is characterized by mutations in genes such as BIN1, leading to defects in muscle cell membrane remodeling. Histologically, it is defined by the presence of centrally located nuclei in muscle fibers, which is atypical for normal muscle tissue. This condition falls under the classification of centronuclear myopathies, a group of congenital myopathies with similar histological features. Epidemiologically, it is a rare disorder with a prevalence of approximately 1 in 100,000 individuals. The disease course is progressive, with symptoms worsening over time, particularly affecting respiratory and skeletal muscles. Management focuses on symptomatic relief and supportive therapies to improve quality of life.
Autosomal recessive centronuclear myopathy Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness in autosomal recessive centronuclear myopathy typically manifests as difficulty in performing tasks that require muscle strength, such as climbing stairs or lifting objects. This weakness is caused by disruptions in the muscle fibers due to mutations affecting proteins like BIN1, which are crucial for muscle function. Over time, muscle weakness may progress, leading to increased difficulty in mobility and daily activities. Patients often require physical therapy and assistive devices to manage this symptom and maintain independence.
Hypotonia presents as decreased muscle tone, resulting in a floppy appearance and poor posture control. This symptom arises from the impaired function of muscle cells due to genetic mutations affecting structural proteins. As the condition progresses, hypotonia can lead to challenges in motor development and coordination. Early intervention with physical therapy can help improve muscle tone and enhance motor skills.
Delayed motor milestones are observed as a lag in achieving developmental tasks such as sitting, crawling, or walking. This delay is due to muscle weakness and hypotonia, which hinder the normal progression of motor skills. Over time, children may catch up with peers, but some may continue to experience difficulties. Supportive therapies, including physical and occupational therapy, are essential to aid in motor development.
Common
Respiratory difficulties can manifest as shortness of breath or reduced lung capacity, particularly during exertion. These issues are caused by weakness in the respiratory muscles, which are also affected by the genetic mutations. As the disease progresses, respiratory function may decline, necessitating interventions such as respiratory therapy or mechanical ventilation. Regular monitoring and respiratory support can significantly improve quality of life.
Fatigue is a common symptom, characterized by a persistent feeling of tiredness and lack of energy. It results from the increased effort required to perform daily activities due to muscle weakness. Over time, fatigue can worsen, impacting the patient's ability to engage in work or social activities. Management includes energy conservation techniques and tailored exercise programs to improve stamina.
Skeletal deformities, such as scoliosis or joint contractures, may develop as a result of muscle weakness and imbalance. These deformities occur because the muscles cannot adequately support the skeletal structure, leading to abnormal growth or positioning. As the condition progresses, these deformities can become more pronounced, affecting posture and mobility. Orthopedic interventions and physical therapy can help manage and correct these issues.
Less Common
Oculomotor abnormalities may present as difficulty in controlling eye movements or maintaining focus. These issues arise from weakness in the ocular muscles, which are similarly affected by the genetic mutations. Over time, these abnormalities can impact vision and daily activities such as reading or driving. Vision therapy and corrective lenses may be used to manage these symptoms.
Cardiac involvement, though less common, can manifest as cardiomyopathy or arrhythmias. This occurs due to the involvement of cardiac muscle cells, which may be affected by the same genetic mutations impacting skeletal muscles. As the disease progresses, cardiac symptoms may worsen, requiring medical management and monitoring. Regular cardiac evaluations and appropriate treatments are crucial to prevent complications.
What Causes Autosomal recessive centronuclear myopathy?
Autosomal recessive centronuclear myopathy is primarily caused by mutations in the BIN1 gene, located on chromosome 2q14.3. The BIN1 gene encodes for the protein amphiphysin 2, which is involved in membrane tubulation and endocytosis. Mutations in BIN1 disrupt its interaction with dynamin 2, impairing membrane remodeling and vesicle trafficking. This disruption leads to abnormal T-tubule formation and defective excitation-contraction coupling in muscle cells. As a result, muscle fibers exhibit centralized nuclei and impaired contractile function. The dysfunction in muscle fibers can trigger an inflammatory response, exacerbating muscle damage. Neuroinflammation may further contribute to muscle weakness and atrophy. The degeneration of muscle tissue is not typically associated with white matter changes, but muscle architecture is severely affected. Symptoms often appear as muscle weakness and hypotonia, particularly affecting proximal muscles. The pattern of symptoms is due to the specific involvement of skeletal muscle fibers and their role in movement. Disease severity varies due to differences in mutation type, location, and potential modifier genes. Some patients may experience a milder phenotype, while others have severe muscle weakness and respiratory complications. The variability in clinical presentation is also influenced by environmental factors and genetic background. Understanding these mechanisms is crucial for developing targeted therapies and improving patient outcomes.
How is Autosomal recessive centronuclear myopathy Diagnosed?
Typical age of diagnosis: Autosomal recessive centronuclear myopathy is typically diagnosed in infancy or early childhood when parents notice delayed motor milestones and muscle weakness. Diagnosis can also occur later in life if symptoms are milder and progress slowly.
Clinicians look for signs of muscle weakness, hypotonia, and delayed motor development. A detailed family history is crucial to identify any genetic predisposition or consanguinity. Physical examination often reveals generalized muscle weakness, diminished deep tendon reflexes, and possible facial muscle involvement. This step helps differentiate centronuclear myopathy from other neuromuscular disorders and guides further testing.
Magnetic Resonance Imaging (MRI) of the muscles is commonly used to assess muscle structure. Specific abnormalities such as fatty infiltration and muscle atrophy can be visible. These findings support the diagnosis of centronuclear myopathy by highlighting characteristic muscle changes. Imaging also helps exclude other conditions like muscular dystrophies or inflammatory myopathies.
Creatine kinase levels are often measured, though they may be normal or mildly elevated. Muscle biopsy may be performed to look for centralized nuclei in muscle fibers, a hallmark of the condition. Abnormal results showing centralized nuclei confirm the suspicion of centronuclear myopathy. These results guide the decision to proceed with genetic testing.
Genes such as BIN1 and others associated with centronuclear myopathy are sequenced. Mutations like missense, nonsense, or splice site mutations are identified. Positive results confirm the diagnosis and allow for precise genetic counseling. Genetic testing informs family planning and helps identify carriers within the family.
Autosomal recessive centronuclear myopathy Treatment Options
Corticosteroids are used to reduce inflammation and slow muscle degeneration. They work by modulating the immune response and stabilizing muscle cell membranes. Prednisone is a commonly used corticosteroid in this context. Clinical evidence shows variable efficacy, with some patients experiencing improved muscle strength. Limitations include potential side effects such as weight gain, osteoporosis, and immunosuppression.
Techniques such as stretching, strengthening exercises, and aquatic therapy are employed. The goal is to maintain muscle function and prevent contractures. Sessions are typically conducted 2-3 times a week, lasting 30-60 minutes each. Measurable outcomes include improved range of motion and muscle strength. Long-term benefits include enhanced quality of life and delayed progression of muscle weakness.
Surgery is indicated for severe contractures that limit mobility. The procedure involves cutting and lengthening tendons to improve joint movement. Expected benefits include increased range of motion and improved functional ability. Surgical risks include infection, nerve damage, and recurrence of contractures. Post-operative care involves physical therapy to maintain surgical gains.
The care team includes neurologists, physiotherapists, occupational therapists, and social workers. Interventions focus on optimizing daily function and providing adaptive equipment. Psychosocial support includes counseling and support groups for patients and families. Family education covers disease management and genetic counseling. Long-term monitoring involves regular assessments to adjust care plans as needed.
When to See a Doctor for Autosomal recessive centronuclear myopathy
- Severe respiratory distress — this could indicate respiratory muscle weakness requiring immediate medical intervention.
- Sudden loss of mobility — this may suggest acute muscle deterioration or a neurological event needing urgent evaluation.
- Severe muscle pain or swelling — this could indicate rhabdomyolysis or another serious muscle condition requiring emergency care.
- Progressive muscle weakness — this is significant as it may indicate disease progression and should prompt a medical review.
- Difficulty swallowing — this could lead to nutritional deficiencies or aspiration and needs assessment by a healthcare provider.
- Frequent falls — this may suggest worsening muscle control and should be discussed with a doctor to prevent injury.
- Mild muscle fatigue — monitor for any increase in severity or frequency and report changes to your healthcare provider.
- Occasional muscle cramps — keep track of triggers and frequency, and discuss with your doctor if they become more frequent.
Autosomal recessive centronuclear myopathy — Frequently Asked Questions
Is this condition hereditary?
Autosomal recessive centronuclear myopathy is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with this condition are usually carriers, meaning they have one mutated gene but do not show symptoms. The probability of passing the condition to children is 25% if both parents are carriers. De novo mutations are not typically associated with this condition. Genetic counseling is recommended for affected families to understand inheritance patterns and carrier testing.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the age of onset and severity of symptoms. Early-onset forms may have a more severe prognosis, while later-onset forms can have a more stable course. Respiratory complications are a common cause of mortality. Treatment and supportive care can improve quality of life and potentially extend survival. Realistic expectations should include ongoing management and adaptation to progressive symptoms.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, muscle biopsy, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months to years. Neurologists and geneticists are commonly consulted during the diagnostic process. Delays in diagnosis may occur due to symptom overlap with other neuromuscular disorders. Genetic testing confirming mutations in relevant genes finally confirms the diagnosis.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and other novel approaches for treating centronuclear myopathy. Clinical trials can be found on ClinicalTrials.gov by searching for centronuclear myopathy. Patients should ask their doctors about eligibility for trials and potential benefits and risks. While promising, new treatments may take several years to become widely available. Staying informed about ongoing research is crucial for accessing new therapies.
How does this condition affect daily life and activities?
The condition can significantly impact mobility, requiring assistive devices or modifications for self-care. Educational accommodations may be necessary for children with the condition. Social and emotional challenges include coping with physical limitations and potential isolation. Family members may experience increased caregiving responsibilities. Supportive therapies and community resources can help manage daily challenges and improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.
Böhm J, Biancalana V, Malfatti E et al. · Brain · 2014 · PMID: 25260562
- 2.Neuromuscular blocking effects of vecuronium in dogs with autosomal-recessive centronuclear myopathy.
Martin-Flores M, Paré MD, Tomak EA et al. · Am J Vet Res · 2015 · PMID: 25815571
- 3.SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs.
Pelé M, Tiret L, Kessler JL et al. · Hum Mol Genet · 2005 · PMID: 15829503
- 4.Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy.
Nicot AS, Toussaint A, Tosch V et al. · Nat Genet · 2007 · PMID: 17676042
- 5.[Mutations in amphiphysin 2 (BIN1) cause autosomal recessive centronuclear myopathy].
Toussaint A, Nicot AS, Mandel JL et al. · Med Sci (Paris) · 2007 · PMID: 18154705
- 6.X-linked myotubular and centronuclear myopathies.
Pierson CR, Tomczak K, Agrawal P et al. · J Neuropathol Exp Neurol · 2005 · PMID: 16042307
- 7.Severe phenotype of a patient with autosomal recessive centronuclear myopathy due to a BIN1 mutation.
Mejaddam AY, Nennesmo I, Sejersen T · Acta Myol · 2009 · PMID: 20476667
- 8.Bridging integrator 1 (Bin1) deficiency in zebrafish results in centronuclear myopathy.
Smith LL, Gupta VA, Beggs AH · Hum Mol Genet · 2014 · PMID: 24549043
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-20